The Data on AI
Minneapolis, MN
Our estimates on data scientist numbers for Bio-Techne trace back to several sources that we check on a monthly basis, including the company's website, career boards and other methods.
The number of data scientists a company has is important because it reflects its capability to innovate, scale AI initiatives, and leverage data-driven decision-making to maintain a competitive edge in AI development and application.
AI Mentions in Quarterly Earnings Calls (2017-Q3 to 2022-Q3): 0.0
AI Mentions in Quarterly Earnings Calls (2022-Q4 to current): 0.8
Post ChatGPT Release, AI Mentions Moved 0.0 Standard Deviations
Bio-Techne holds 0 patents focused on AI subjects. We have combed through the records of the United States Patent Office for filings related to AI for more than 500 companies. We consider a qualifying patent to be one that primarily concerns artificial intelligence or machine learning. Patents that simply mention these things do not figure in our count.
Examining CapEx shows how much Bio-Techne invests in physical assets, highlighting its commitment to growth and the infrastructure needed to support AI initiatives.
This graph provides a comprehensive view of Bio-Techne's strategic allocation of resources by comparing free cash flow, R&D costs, and CapEx over time, highlighting how investments in AI and innovation are balanced against financial health and infrastructure commitments. It offers insights into whether a company is sustainably prioritizing AI development amidst its broader financial strategies.